Photo from wikipedia
Monitoring for substandard medicines by regulatory agencies is a key post‐market surveillance activity. It is important to prioritise critical product defects for review to ensure that prompt risk mitigation actions… Click to show full abstract
Monitoring for substandard medicines by regulatory agencies is a key post‐market surveillance activity. It is important to prioritise critical product defects for review to ensure that prompt risk mitigation actions are taken.
Keywords:
risk classification;
substandard;
classification model;
prioritising management;
substandard medicines;
model prioritising
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!